

Welcome to the CADTH Virtual Exhibit Page

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies, including drugs, diagnostic tests, medical, dental, and surgical devices and procedures, and clinical interventions. In addition to evidence, we also provide advice, recommendations, and tools.

Substance Use Disorders– see attached PDF

ON THE TOPIC OF

Substance Use Disorder

CADTH Evidence Driven.

Here is a selection of products on the topic of substance use disorder. These and other CADTH products are open access and available at cadth.ca. For more information, please contact requests@cadth.ca. The inclusion of reports on particular drugs or other health technologies in this list does not indicate that CADTH endorses these technologies.

Benzodiazepines

- Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Health Facilities or Emergency Department Settings (*Rapid Review*, Aug. 2021)
- Management of Patients Co-Prescribed Benzodiazepines and Opioids (*Summary of Abstracts*, May 2021)
- Benzodiazepines for the Treatment of Adults With Mental Health Conditions or Sleep Disorders Guidelines (*Summary of Abstracts*, Aug. 2019)

Pharmacological Treatments for Substance Use Disorder

- Injectable Opioid Agonist Treatment for Patients With Opioid Dependence: A Review of Clinical and Cost-Effectiveness (*Rapid Review*, June 2020)
- Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients With Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Rapid Review*, July 2019)
- Buprenorphine for Opioid Use Disorders During Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines (*Rapid Review*, May 2019)
- Gabapentin, Phenobarbital, Diazepam, and Lorazepam for the Treatment of Alcohol Withdrawal: Clinical Effectiveness and Guidelines (*Summary of Abstracts*, June 2020)

- Naltrexone for Alcohol Addiction: Clinical Effectiveness, Cost Effectiveness, and Guidelines (*Summary of Abstracts*, June 2019)

Other Treatments for Substance Use Disorder

- Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders (*Rapid Review*, June 2021)
- e-Therapy Interventions for the Treatments of Substance Use Disorders and Other Addictions: A Review of Clinical Effectiveness (*Rapid Review*, June 2018)

Substance Use Disorder Treatment Programs

- Programs for the Treatment of Opioid Addiction in Canada (*Environmental Scan*, Sept. 2019)
- Treatment Programs for Substance Use Disorder (*Rapid Review*, June 2021)
- Residential Treatment for Substance Use Disorder: A Review of Clinical Effectiveness (*Rapid Review*, Jan. 2019)
- Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines (*Rapid Review*, Nov. 2017)
- Managed Alcohol Programs for Patients With Alcohol Addiction: Clinical Effectiveness (*Summary of Abstracts*, Jan. 2017)

Evidence on Mental Health

Here you'll find an up-to-date collection of our products in the area of mental health. These range from short reports to in-depth systematic reviews and various tools and resources geared to translating mental health research evidence into action. Topics covered include substance related & addictive disorders and trauma- and stressor-related disorders. <https://cadth.ca/mentalhealth>

Stay connected to CADTH

Subscribe and stay up-to-date with the information that matters to you. CADTH produces a number of newsletters and updates to keep you informed about the release of our latest reports and recommendations, opportunities for input and feedback, and our special events, including our annual CADTH Symposium. Sign-up [here](#).

Questions or Requests, please contact:

Jill Sutherland
Manitoba Liaison Officer
Email: jillsu@cadth.ca
Phone: 204 510 8922